Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | SLC28A3 | Q9HAS3 | 3/20 | 0.46 |
| ▸ | TYR | P14679 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | ESR1 | P03372 | 1/20 | 0.42 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3175387 | 1.00 | POLB (0.47) | POLBSLC28A3TYRL3MBTL1MAPT | |
| SCHEMBL13456979 | 0.84 | AKR1B1 (0.56) | SLC28A3TYRL3MBTL1 | |
| SCHEMBL4416998 | 0.84 | AKR1B1 (0.56) | SLC28A3TYRL3MBTL1 | |
| SCHEMBL1315483 | 0.84 | AKR1B1 (0.56) | SLC28A3TYRL3MBTL1 | |
| SCHEMBL16906157 | 0.84 | AKR1B1 (0.56) | SLC28A3TYRL3MBTL1 | |
| SCHEMBL4620889 | 0.84 | AKR1B1 (0.56) | SLC28A3TYRL3MBTL1 | |
| SCHEMBL1263104 | 0.84 | AKR1B1 (0.56) | SLC28A3TYRL3MBTL1 | |
| SCHEMBL11986810 | 0.84 | AKR1B1 (0.56) | SLC28A3TYRL3MBTL1 | |
| SCHEMBL22504483 | 0.84 | AKR1B1 (0.56) | SLC28A3TYRL3MBTL1 | |
| SCHEMBL31689142 | 0.84 | TYR (0.58) | SLC28A3TYR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100016244-A1 | D-GLUCOPYRANOSE 1-[3,5-BIS (1,1-DIMETHYLETHY)-4-HYDROXYBENZOATE] AND ITS DERIVATIVES, PREPARATION AND USE THEREOF | RDW PHARMA (FR) | 2010-01-21 | — | — | US | claimed |
| US-20100016244-A1 | D-GLUCOPYRANOSE 1-[3,5-BIS (1,1-DIMETHYLETHY)-4-HYDROXYBENZOATE] AND ITS DERIVATIVES, PREPARATION AND USE THEREOF | RDW PHARMA (FR) | 2010-01-21 | — | — | US | disclosed |
| US-20100016244-A1 | D-GLUCOPYRANOSE 1-[3,5-BIS (1,1-DIMETHYLETHY)-4-HYDROXYBENZOATE] AND ITS DERIVATIVES, PREPARATION AND USE THEREOF | RDW PHARMA (FR) | 2010-01-21 | — | — | US | disclosed |
| EP-2041152-A1 | D-GLUCOPYRANOSE 1-[3,5-BIS(1,1-DIMETHYLETHYL)-4-HYDROXYBENZOATE] COMPOUND AND ITS DERIVATIVES, PREPARATION THEREOF AND USES THEREOF | RDW Pharma (FR) | 2009-04-01 | — | — | EP | disclosed |
| EP-2041152-A1 | D-GLUCOPYRANOSE 1-[3,5-BIS(1,1-DIMETHYLETHYL)-4-HYDROXYBENZOATE] COMPOUND AND ITS DERIVATIVES, PREPARATION THEREOF AND USES THEREOF | RDW Pharma (FR) | 2009-04-01 | — | — | EP | disclosed |
| WO-2008000920-A1 | D-GLUCOPYRANOSE 1-[3,5-BIS(1,1-DIMETHYLETHYL)-4-HYDROXYBENZOATE] COMPOUND AND ITS DERIVATIVES, PREPARATION THEREOF AND USES THEREOF | RDW PHARMA (FR) | 2008-01-03 | — | — | WO | disclosed |
| WO-2008000920-A1 | D-GLUCOPYRANOSE 1-[3,5-BIS(1,1-DIMETHYLETHYL)-4-HYDROXYBENZOATE] COMPOUND AND ITS DERIVATIVES, PREPARATION THEREOF AND USES THEREOF | RDW PHARMA (FR) | 2008-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016244-A1 | D-GLUCOPYRANOSE 1-[3,5-BIS (1,1-DIMETHYLETHY)-4-HYDROXYBENZOATE] AND ITS DERIVATIVES, PREPARATION AND USE THEREOF | G6PD, PIGS, GALE | POLB 903/4885SLC28A3 3554/4885TYR 1699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.